Status:
COMPLETED
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
Lead Sponsor:
Integrative Skin Science and Research
Collaborating Sponsors:
Actera
Conditions:
Hyperpigmentation
Post-inflammatory Hyperpigmentation
Eligibility:
All Genders
14-45 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.
Detailed Description
Hyperpigmentation is characterized as an increase in pigment on the skin and is a common skin condition in individuals with skin types III to VI on the Fitzpatrick skin classification scale. Hyperpigm...
Eligibility Criteria
Inclusion
- Males and females between the ages of 14 years of age until 55 years of age
- Individuals experiencing 3 different areas minimum of facial post-inflammatory hyperpigmentation in those with acne
Exclusion
- Individuals who are pregnant or breastfeeding.
- Prisoners.
- Adults unable to consent.
- Those who are unwilling to discontinue hydroquinone, vitamin A/C/E, azelaic acid, kojic acid, bakuchiol, licorice root, retinol, niacinamide, alpha arbutin, and oral or topical tranexamic acid for two weeks to meet the washout criteria prior to enrolling and for the duration of the study.
- Subjects with any of the following facial cosmetic treatments within the past 3 months or those who are unwilling to withhold the following facial cosmetic treatments during study including microdermabrasion, intense pulsed light (IPL), peels, laser treatments, acid treatments, or any other medical treatment administered by a physician or skin care professional which is designed to improve skin pigmentation.
- Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study.
- Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 11 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06080035
Start Date
November 6 2023
End Date
January 11 2024
Last Update
August 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Integrative Skin and Research
Sacramento, California, United States, 95815